Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Stephen Huo"'
Autor:
Doris K. Hansen, Xiaoxiao Lu, Omar Castaneda Puglianini, Sonja Sorensen, Saad Z. Usmani, Eileen Zhang, Stephen Huo, Yan Zhang, Zaina P. Qureshi, Sundar Jagannath
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionCiltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM). In the phase 3 trial, CARTITUDE-4 (NCT04181827), cilta-cel demonstrated improved e
Externí odkaz:
https://doaj.org/article/faef266a18e64f2baab90aadac26c543
Autor:
Doris K. Hansen, Binod Dhakal, Mehdi Hamadani, David Dingli, Tania Jain, Carol Ann Huff, Murali Janakiram, Yi-Hsuan Liu, Kevin C. De Braganca, Nicole Lodowski, Jennifer Sander, Peter Okorozo, Lindsay McFarland, Matthew Perciavalle, Stephen Huo, Zaina P. Qureshi, Krina K. Patel
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionChimeric antigen receptor (CAR) T-cell therapy (CAR T therapy) is a treatment option for patients with relapsed or refractory multiple myeloma that has led to unprecedented treatment outcomes. Among CAR T therapies available, ciltacabtage
Externí odkaz:
https://doaj.org/article/7ded4f0c8f524a62a65d7cce93bbdc68
Autor:
Jay R. Hydren, Dee Lin, Nathan W. Sweeney, Bingcao Wu, Nina Kim, Saurabh Patel, Douglas W. Sborov, Jesus G. Berdeja, Larry D. Anderson, Stephen Huo, Jorge Arturo Hurtado Martínez, Jennifer M. Ahlstrom
Publikováno v:
Frontiers in Health Services, Vol 4 (2024)
BackgroundAdvances in multiple myeloma (MM) treatment have shifted the therapeutic landscape. Understanding patients' perspectives can assist physicians in helping patients make informed decisions. This study aimed to understand the patient decision-
Externí odkaz:
https://doaj.org/article/a64d3a4c71e84564bfe78b47bcdd3da0
Autor:
Doris K Hansen MD, Todd Bixby MBA, RPh, Karen Fixler, Lisa Shea MPH RD, Christine Brittle PhD, Kimberly Brunisholz PhD, MST, Yi-Hsuan Liu PhD, MS, RD, Jinhai Stephen Huo PhD, MD, MsPH
Publikováno v:
Journal of Patient Experience, Vol 10 (2023)
A qualitative study of the experiences of patients who received autologous stem cell transplant (ASCT) for the treatment of multiple myeloma (MM) was conducted to better understand their MM disease journey, including first symptoms, diagnosis, ASCT,
Externí odkaz:
https://doaj.org/article/e5ceb884f67e40de9437428cb410da65
Autor:
Jay R. Hydren, Dee Lin, Jorge Arturo Hurtado, Nathan W. Sweeney, Bingcao Wu, Katharine Gries, Nina Kim, Saurabh Patel, Douglas W. Sborov, Jesus Berdeja, Larry D. Anderson, Jinhai Stephen Huo, Jennifer M. Ahlstrom
Publikováno v:
HemaSphere, Vol 7, p e17730f9 (2023)
Externí odkaz:
https://doaj.org/article/d18c4a806e474e1f90dceff1abafdac2
Autor:
David F. McDermott, Michael B. Atkins, Brian Stwalley, Viviana Del Tejo, Stephen Huo, Laurence Albiges, Bernard Escudier, Hans J. Hammers, Brian I. Rini, Toni K. Choueiri, Elizabeth R. Plimack, Martin H. Voss, Yoshihiko Tomita, Chung-Han Lee, Nizar M. Tannir, Robert J. Motzer, Lillian Werner, Thomas Powles, Charlene M. Mantia, Opeyemi A. Jegede, Meredith M. Regan
Supplementary Data from Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e49ca13be123ef92c935f63a88bc82d
https://doi.org/10.1158/1078-0432.22483101.v1
https://doi.org/10.1158/1078-0432.22483101.v1
Autor:
Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, Cristina Suárez, Maria T. Bourlon, Pedro C. Barata, Shuchi Gulati, Stephen Huo, Flavia Ejzykowicz, Steven I. Blum, Viviana Del Tejo, Melissa Hamilton, Jessica R. May, Ella X. Du, Aozhou Wu, Pavol Kral, Cristina Ivanescu, Andi Chin, Keith A. Betts, Chung-Han Lee, Toni K. Choueiri, David Cella, Camillo Porta
Publikováno v:
European Urology Oncology.
Autor:
Daniel M, Geynisman, Ella X, Du, Xiaoran, Yang, Selvam R, Sendhil, Viviana Del, Tejo, Keith A, Betts, Stephen, Huo
Publikováno v:
Future Oncology. 18:1219-1234
Aims: To assess grade 3/4 adverse events (AEs) and costs of first-line nivolumab plus ipilimumab versus sunitinib in advanced or metastatic renal cell carcinoma. Methods: Individual patient data from the all treated population in the CheckMate 214 tr
Autor:
Bradley McGregor, Daniel M Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T Bourlon, Viviana Del Tejo, Ella X Du, Xiaoran Yang, Selvam R Sendhil, Keith A Betts, Stephen Huo
Publikováno v:
Scientia
Background Despite 4 approved combination regimens in the first-line setting for advanced renal cell carcinoma (aRCC), adverse event (AE) costs data are lacking. Materials and Methods A descriptive analysis on 2 AE cost comparisons was conducted usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24a1624d6b56737a87630493fac99671
https://hdl.handle.net/11351/9391
https://hdl.handle.net/11351/9391
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 41:259